Print

Purpose

The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Eligibility Criteria:

- Enrolled in the WU-PE-CGS study (IRB#202106129); that eligibility entails:

- Diagnosis of cholangiocarcinoma

- Diagnosis of multiple myeloma, must be African American

- Diagnosis of colorectal cancer, must be African American and age 65 or older at
time of diagnosis

- At least 18 years old.

- Able to understand an IRB-approved informed consent document and agree to
participation

- Have access to a personal computer, tablet or mobile device

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Health Services Research
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Intervention: Genetics Advisor Online Tool 		The Intervention group will receive the expanded Genetics Advisor decision aid.
  • Other: Genetics Advisor Decision Aid
    Participants will be given the option to receive different types of results from genomic sequencing. The participants will be given access to a web-based decision aid that elicits participants' values and preferences for receiving results from cancer genomic sequencing to guide them making a decision about what types of results they would like to receive. Participants will be able to choose to receive: (1) no results, or any combination of (2) biomarker information from cancer cells, (3) inherited mutations related to cancer, and (4) inherited mutations related to other medical issues.
Active Comparator
Control: Standard developed materials 		The control group will receive a description of each type of genomic sequencing result they could receive using the standard informed consent process for the return-of-results protocol.

Recruiting Locations

Washington University in St. Louis and nearby locations

Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
Contact:
Erin Linnenbringer, Ph.D., MS
314-747-1966
elinnen@wustl.edu

More Details

NCT ID
NCT06910670
Status
Recruiting
Sponsor
Washington University School of Medicine

Study Contact

Erin Linnenbringer, Ph.D., MS
314-747-1966
elinnen@wustl.edu

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.